Subscribe
shutterstock_1513301072_bernsten
Bernsten / Shutterstock.com
5 May 2022Alex Baldwin

WTO reveals draft of COVID-19 IP waiver

A proposal for the COVID-19 vaccine waiver has been prepared for approval by the wider members of the World Trade Organisation (WTO).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

article
WTO releases draft COVID-19 response after ‘very difficult process’
14 June 2022   The World Trade Organization has issued draft texts relating to its IP response to the COVID-19.
Europe
UK implored to back COVID-19 IP waiver at WTO
11 March 2021   The UK has been urged to back a proposed IP waiver related to COVID-19 treatments before the World Trade Organisation by business leaders, academics, economists and trade unions.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

More features

The Quintara decision: Defining trade secrets in federal cases
To disclose or not: Pharma patents face new AI reality
Trade secrets go global: How brand owners face a high-stakes battlefront
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Former pharma GC brings in-house perspective to McGuireWoods
Sandoz eyes US biosimilar launch as Regeneron settles
Killing the golden goose of US drug innovation (Part I): Follow the money
Buchalter brings in new partner to head up medtech